Developing biomarkers to predict benefit from HGF / MET pathway inhibitors

Hartmut Koeppen, Sandra Rost, Robert L. Yauch · The Journal of Pathology · 2013

Activation of the MET signalling pathway is critical in regulating multiple cellular processes underlying tumourigenic growth and has represented an attractive target for therapeutic intervention in cancer. Early stage clinical studies of multiple agents targeting this pathway have been undertaken, frequently in unselected patient cohorts with variable results. Promising data in patient subgroups in these studies indicate the need for predictive biomarkers to identify the patients most likely to benefit from these therapies. In this review, we discuss the current knowledge of mechanisms of MET activation, the status of the clinical evaluation of MET-targeted therapies, the associated efforts to identify and validate biomarkers, and the considerations and challenges for potential development of companion diagnostics.

Cited by 37 works. doi:10.1002/path.4268 Open-access PDF

Authors

References